Mouse hepatitis virus (MHV) isolates JHM.WU and JHM.SD promote severe central nervous system disease. However, while JHM.WU replicates robustly and induces hepatitis, JHM.SD fails to replicate or induce pathology in the liver. These two JHM variants encode homologous proteins with few polymorphisms, and little is known about which viral proteins(s) is responsible for the liver tropism of JHM.WU. We constructed reverse genetic systems for JHM.SD and JHM.WU and, utilizing these fulllength cDNA clones, constructed chimeric viruses and mapped the virulence factors involved in liver tropism. Exchanging the spike proteins of the two viruses neither increased replication of JHM.SD in the liver nor attenuated JHM.WU. By further mapping, we found that polymorphisms in JHM.WU structural protein M and nonstructural replicase proteins nsp1 and nsp13 are essential for liver pathogenesis. M protein and nsp13, the helicase, of JHM.WU are required for efficient replication in vitro and in the liver in vivo. The JHM.SD nsp1 protein contains a K194R substitution of Lys194, a residue conserved among all other MHV strains. The K194R polymorphism has no effect on in vitro replication but influences hepatotropism, and introduction of R194K into JHM.SD promotes replication in the liver. Conversely, a K194R substitution in nsp1 of JHM.WU or A59, another hepatotropic strain, significantly attenuates replication of each strain in the liver and increases IFN-␤ expression in macrophages in culture. Our data indicate that both structural and nonstructural proteins contribute to MHV liver pathogenesis and support previous reports that nsp1 is a Betacoronavirus virulence factor.
pathogenesis, and hepatotropic revertants had compensatory mutations in the heptad repeat domain of the S2 subunit (6) . A long hypervariable domain within the amino-terminal spike subunit S1 has been associated with the ability to spread independently of the viral receptor CEACAM1a and with the high neurovirulence of the JHM.SD strain (7) . Substitutions within the heptad repeat domains of the spike have caused defects in spike-induced cell-tocell fusion and limited spread in the brain (8, 9) . In addition, the replicase and other nonstructural proteins have also been identified as liver virulence factors. A mutation within the ADP-ribose-1Љ-phosphatase (ADRP), the macrodomain of the nsp3 protein, that abolished enzymatic activity attenuated hepatitis compared to wild-type (wt) virus but did not significantly reduce replication in the liver (10) , and it recently was found to reduce replication and pathogenesis in the CNS (11) . Accessory protein ns2 is a 2=,5=phosphodiesterase (PDE) that cleaves 2=,5=-oligoadenylates, thereby blocking the activation of RNase L. Mutation of ns2 abolishes PDE activity and attenuates viral replication in the liver and the consequent hepatitis without substantially affecting CNS infection (12) .
The JHM.SD isolate of MHV is highly neurovirulent but fails to replicate in the liver and cause hepatitis even when inoculated at doses as high as 10 5 PFU (13) ; in contrast, the dualtropic (highly neurotropic/highly hepatotropic) JHM.WU replicates to very high titer in the liver (14) . JHM.SD encodes wild-type nsp3-ADRP and ns2-PDE but still does not cause hepatitis, suggesting that additional proteins mediate liver pathogenicity. In order to identify such virulence determinants, we used a reverse genetic approach and constructed full-length cDNA clones representing JHM.WU (14, 15) and JHM.SD (16) . By exchanging fragments of the genomes and constructing site-directed mutants, we identified the nsp1, nsp13, and M proteins as contributors to JHM replication in the liver.
MATERIALS AND METHODS
Cell lines, mice, and viruses. Recombinant JHM.SD (RJHM/A) (13, 16) , which was based on the MHV-4 isolate of JHM (16) and previously recovered by RNA-targeted recombination, and JHM.WU (previously called wb-3) (14, 15) were used as templates to generate infectious cDNA clones. Mildly neurotropic and moderately hepatotropic recombinant rA59 was derived from an existing infectious cDNA clone (17, 18) . The mouse 17Cl-1 and L2 fibroblast cell lines and baby hamster kidney cells constitutively expressing MHV receptor CEACAM-1 (BHK-MHVR) were cultured as described previously (17, 19) . Primary bone marrow-derived macrophages (BMM) were generated from the hind limbs of B6 or type I interferon receptor-deficient (IFNAR Ϫ/Ϫ ) mice as described previously and cultured in Dulbecco modified Eagle medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 1 mM pyruvate, and 30% L929 cell-conditioned medium for 6 days before infection (20) . BMM cultures were routinely Ն99% pure as assessed by positive staining for expression of CD11b and negative staining for expression of CD11c. C57BL/6 (B6) mice were purchased from the National Cancer Institute (Frederick, MD) and bred in the University of Pennsylvania animal facility according to procedures approved by the University IACUC.
Construction of JHM.SD and JHM.WU infectious cDNA clones. The strategy employed to construct the infectious cDNA clone of JHM.SD was as described previously for A59 (17) with slight modification. Intracellular RNA was extracted from recombinant JHM.SD (RJHM/A)-infected 17Cl-1 cells and reverse transcribed using SuperScript II (Invitrogen, Carlsbad, CA) and random hexamer primers. The cDNA was amplified by PCR with Expand Long TAQ polymerase (Roche, Mannheim, Germany) to create six fragments (A to F) ( Fig. 1 ). Fragment A was cloned into pCR4 TOPO TA (Invitrogen) and fragments B through F into pSMART-LCAmp (Lucigen). Fragment G was derived from viral sequences in pJHM (21) , which were modified to add a BsmBI site at the 5= end. All of the BsmBI restriction sites encoded within the genome were removed by PCR-based site-directed mutagenesis. BsmB1 restriction sites flanking each of the fragments, as well as the EcoRV site at the 5= end of fragment A and the PacI site at the 3= end of fragment G, were introduced during the construction and were used for full-length in vitro genome assembly ( Fig. 1) .
The infectious JHM.WU cDNA clone was constructed using the JHM.SD fragments as a scaffold. Fragments A, C, F, and G were PCR amplified from intracellular RNA extracted from JHM.WU (wb-3)-infected 17Cl-1 cells (15) and inserted into the JHM.SD plasmids in place of the corresponding fragments. The endogenous BsmBI sites were removed as for JHM.SD ( Fig. 1 ). JHM.SD fragments B, D, and E were used for JHM.WU because the proteins encoded by these fragments have complete amino acid sequence identity between the two isolates. All of the primers used for plasmid construction and mutation are available upon request. All of the chimeric and mutant clones used for virus recovery were verified by nucleotide sequencing. A schematic diagram of the construction of the rJHM.SD and rJHM.WU full-length clones is shown in Fig. 1 .
Recovery of recombinant viruses. The full-length genomic cDNAs were assembled and the recombinant viruses were recovered as previously described (17, 18) . Briefly, JHM.SD and JHM.WU plasmids A through G were digested with BsmBI and isolated from agarose gels. Equal molar ratios of each fragment were ligated (about 2 g of DNA total) with T4 DNA ligase overnight at 16°C. The ligated DNA was chloroform extracted and precipitated. In vitro transcription driven by a T7 promoter present directly upstream of the viral DNA was carried out using the mMessage FIG 1 MHV genome organization and the full-length JHM.WU and JHM.SD cDNA clones. The full-length viral genomes were amplified as fragments A to G, which were cloned individually into plasmids. BsmBI type II restriction sites were added to the internal termini of each of the fragments and used for assembly. A T7 promoter for in vitro RNA transcription was added to the 5= end of fragment A. The full-length genomic cDNAs were assembled in vitro and the viruses recovered from each designated rSD for JHM.SD and rWU for JHM.WU. mMachine T7 transcription kit (Ambion) (17) . The nucleocapsid gene was amplified from each G plasmid with primers bearing the SP6 promoter and then similarly transcribed with the mMessage mMachine SP6 transcription kit. The viral genome transcripts were combined with the N gene transcripts and electroporated into the BHK-MHVR with three pulses of 850 V at 25 F using a Gene Pulser II electroporator (Bio-Rad, Hercules, CA), and these cells were overlaid on nearly confluent L2 cells. When viral cytopathology was observed, the combined cells and supernatant were harvested. Recombinant viruses were plaque purified and amplified in 17Cl-1 cells. Recombinant JHM.SD will be referred to as rSD and JHM.WU as rWU here.
Generation of chimeric and mutant recombinant viruses. To generate the chimeric JHM.SD expressing the spike gene of WU (rSD.S WU ), the portion of the spike gene containing the JHM.WU polymorphism was amplified from the JHM.WU G fragment and cloned into the AvrII and SphI sites of the JHM.SD G fragment (see Fig. 3A ). The chimeric JHM. WU with the entire JHM.SD spike gene (rWU.S SD ) was constructed by replacing the BamHI-SphI fragment containing the spike gene. The chimeric JHM.SD viruses containing the F and/or G fragment of JHM.WU were constructed by combining JHM.SD fragments A through E with the F and/or G fragment from JHM.WU. The resulting viruses were designated rSD.F WU , rSD.G WU , and rSD.F WU G WU . Similarly, rWU.A SD and rWU.C SD were generated by replacing the A and C fragments, respectively, of JHM.WU with those of JHM.SD. Single mutations were constructed by PCR-based site-directed mutagenesis and verified by nucleotide sequencing.
Viral replication kinetics. L2 or BMM cells were infected with each virus at a multiplicity of infection (MOI) of 0.01 or 1 PFU/cell, as indicated. After 1 h, the cells were washed and cultured with DMEM supplemented with 10% FBS. The culture supernatants were collected at the indicated time points, and the virus titers were determined by plaque assays on L2 cells (22) .
ELISA. IFN-␤ protein in the supernatant of MHV-infected BMM was quantified using a commercial capture enzyme-linked immunosorbent assay (ELISA) kit (PBL Laboratories, Piscataway, NJ) according to the manufacturer's instructions.
Mouse infections. Viruses were diluted into phosphate-buffered saline (PBS) containing 0.75% bovine serum albumin. Four-week-old B6 mice were anesthetized with isoflurane (IsoFlo; Abbott Laboratories) and inoculated intrahepatically (i.h.) or intracranially (i.c.) with each virus at the indicated dose. On day 5 postinfection (p.i.), the mice were sacrificed and perfused with PBS. The livers and/or brains were harvested and homogenized and their virus titers determined by plaque assays on L2 cells as previously described (23) . All mouse procedures were reviewed and approved by the University of Pennsylvania IACUC.
Histology. The livers were isolated and fixed in 4% paraformaldehyde, embedded in paraffin, and sectioned. Liver sections were stained with hematoxylin and eosin.
Statistical analysis. A two-tailed Student t test was performed to assess statistical significance for in vitro experiments. The Mann-Whitney test was used to analyze differences in virus titer in mouse tissues. Any undetectable titer from in vitro or in vivo infection was entered as the limit of detection for the corresponding experiment. All data were analyzed using GraphPad Prism software (GraphPad Software, Inc., CA).
RESULTS

Construction of JHM.SD and JHM.WU reverse genetic systems and comparison of recombinant and parental wild-type viruses.
The construction of the full-length cDNA clones for JHM.SD and JHM.WU (1) is described in detail in Materials and Methods and summarized briefly here. Using the genomic RNA of wt recombinant JHM.SD (RJHM/A) previously generated by targeted recombination (24) as a template, seven DNA fragments (A to G) spanning the entire genome were amplified and cloned into bacterial plasmids. A T7 promoter was introduced at the 5= end of the A fragment ( Fig. 1 ). Cleavage sites for the type II restriction enzyme BsmBI were introduced at the junction sites of each fragment, and all endogenous BsmBI sites were removed by introduction of noncoding mutations ( Fig. 1 ). Other than the nine silent mutations used to remove the BsmBI sites within the genome, the cloned fragments are identical to the sequence of JHM.SD (RJHM/A; GenBank: FJ647219.1). The seven fragments were digested from vectors and assembled into a full-length genomic cDNA. Viral RNA was transcribed using the 5= T7 promoter and electroporated into BHK-MHVR cells to generate the recombinant JHM.SD, which will be referred to herein as rSD.
For construction of the JHM.WU infectious clone, fragments A, C, F, and G were amplified from JHM.WU (wb-3) genomic RNA and cloned into bacterial vectors as described above. Because there were no amino acid difference in the proteins encoded within the B, D, and E fragments of JHM.WU and JHM.SD, the JHM.SD fragments were used to complete the full genomic cDNA of JHM.WU ( Fig. 1 ). Other than the nine silent mutations used to remove the BsmBI sites, and three synonymous point substitutions in nsp1 and nsp3, the cloned fragments are identical to the sequence of JHM.WU (JHM.WU; GenBank: JX169867.1). Recombinant JHM.WU (referred to as rWU) was recovered as for rSD.
To compare the phenotypes of rSD and rWU with those of their parental viruses, we first determined their replication kinetics (at a low MOI, 0.01 PFU/cell) in murine L2 fibroblasts. Neither the kinetics of replication nor the final titer differed between JHM.SD and its infectious-clone counterpart rSD or between JHM.WU and rWU ( Fig. 2A ). Of note, JHM.WU and rWU replicated faster than JHM.SD and rSD and to a peak titer 100-to 1,000-fold higher at 36 h postinfection.
Next, we compared replication of rWU and rSD with that of their respective parental viruses in vivo in mice. Previous studies demonstrated that intracranial (i.c.) inoculation of weanling C57BL/6 (B6) mice with JHM.SD or JHM.WU caused severe encephalitis (13, 15, 16, 25) but that only JHM.WU caused hepatitis (13, 14) . Following i.c. infection of B6 mice, the titer of rSD was approximately 4.7 ϫ 10 6 PFU g Ϫ1 of brain, similar to that of wildtype JHM.SD, while rWU, like JHM.WU, replicated to an approximately 10-fold-higher titer (Fig. 2B ). In both JHM.SD-infected and rSD-infected mice, the viral titers in the liver were below the limit of detection by plaque assay (about 100 PFU g Ϫ1 ); in contrast, approximately 10 6 PFU g Ϫ1 of virus was detected in the livers of JHM.WU-infected and rWU-infected mice (Fig. 2B ). Following intrahepatic (i.h.) inoculation, JHM.WU and rWU replicated in the liver to an even higher titer, approximately 10 7 PFU g Ϫ1 , whereas replication of JHM.SD and rSD was below the level of detection ( Fig. 2C ), as previously observed (24) . Previous studies in our lab had indicated that the extent of hepatitis (inflammation and necrosis) in MHV-infected mice correlates with the extent of infectious virus replication in the liver (24) . Indeed, hematoxylin and eosin staining demonstrated severe liver necrosis in rWUinfected mouse liver, while no obvious liver damage was observed in rSD-infected mice (Fig. 2D ). These results indicated that rSD and rWU reproduced the pathogenesis of their parental isolates JHM.SD and JHM.WU in the mouse model.
Exchange of the JHM.WU and JHM.SD spike proteins does not affect replication in the liver. Relative to the JHM.SD spike, the JHM.WU spike has a 141-amino-acid in-frame deletion (JHM.SD residues 454 to 594) within the S1 subunit hypervariable domain as well as a 1-amino-acid substitution, L48R, within the receptor-binding domain at the amino terminus of the S1 subunit ( Table 1) . To address whether this deletion and mutation affect liver tropism, we exchanged the spike genes of rSD and rWU to generate rSD.S WU and rWU.S SD (Fig. 3A ) and characterized their growth kinetics in L2 cells. Compared to rSD, rSD.S WU replicated to a 10-to 100-fold-higher titer in L2 cells, suggesting that spike substitution enhanced virus production in vitro (Fig. 3B ). Consistent with these data, rWU.S SD displayed a 10-to 100-fold-lower titer than rWU (Fig. 3D) . In contrast to the in vitro results, while both rSD.Swu and rSD failed to replicate in the liver in B6 mice ( Fig. 3C ), rWU and rWU.S SD replicated to similar titers in the liver in B6 mice (Fig. 3E ). Thus, while the spike protein does influence replication kinetics in vitro, spike is not a significant determinant of WU liver tropism.
The 3= JHM.WU genome fragments F and G, encoding some of the nonstructural proteins and all of the structural proteins, enable JHM.SD to replicate in the liver. After finding that the JHM.WU spike protein did not enhance rSD replication in the liver, we investigated which other structural and/or nonstructural proteins might play a role in liver tropism. Thus, we replaced the F and/or G fragment(s) of JHM.SD with the corresponding fragment(s) of JHM.WU to generate rSD.Gwu, rSD.F wu , and rSD. F WU G WU (Fig. 4A ). The G fragment encodes most of the structural proteins, including the nucleocapsid, membrane protein (M), small membrane protein (E), spike, and part of the HE protein ( Fig. 1) ; the F fragment encodes the rest of the HE protein, accessory protein ns2, and a segment of open reading frame (ORF) 1b including the carboxy-terminal portion of replicase protein nsp12 as well as all of nsp13 to -16. Replacement of the G fragment alone or in combination with F conferred efficient replication in L2 cells in vitro, while rSD.F WU did not replicate to a higher titer than rSD (Fig. 4B ). In contrast, in vivo, replacement of either the F or G fragment alone only marginally increased rSD replication in the liver at 5 days postinfection. However, replacement of both the F and G fragments (rSD.F WU G WU ) restored replication to approxi- mately 2.6 ϫ10 5 PFU g Ϫ1 in the liver, about 10-to 50-fold lower than that for rWU ( Fig. 4C) . The JHM.SD nsp13 and M protein sequences attenuate JHM.WU replication in vitro and in the liver. To identify which protein(s) encoded within fragments F and G of JHM.WU is essential to MHV liver replication, we compared the sequences of the proteins encoded by fragments F and G between the two JHM strains ( Table 1 ). In addition to the differences in the spike, discussed above, these included amino acid substitutions in the structural proteins HE and M (fragment G) and the accessory protein ns2 and nonstructural replicase proteins nsp13 and nsp15 (fragment F) (26) (Fig. 5A) . To evaluate the importance of these polymorphisms, we generated recombinant viruses in the JHM.WU background bearing amino acid substitutions found in the JHM.SD genome (Fig. 5A ). Four of these, rWU.HE V408I , rWU.HE I425M,L426F , rWU.ns2 G177D /HE S3R , and rWU.nsp15 V41E , exhibited growth kinetics in L2 cells that were similar to those of rWU ( Fig. 5B and C) and furthermore replicated as efficiently (i.e., with no significant difference) as rWU in mouse liver ( Fig. 5C and E). (The P value for nsp15 versus wt rWU mouse liver replication is 0.0952.) Therefore, the sequence differences in HE, ns2, and nsp15 in the JHM.SD genome did not significantly affect viral replication in the liver.
In contrast, mutations within the M and nsp13 genes conferred phenotypic changes in vitro and in vivo. Two amino acid differences were identified between M proteins of JHM.WU and JHM.SD (Table 1) . To determine their impact on viral replication, we generated recombinant viruses with each or both of the JHM.SD M substitutions in the rWU background. The recombinant viruses containing single substitutions (rWU.M F155L and rWU.M V224A ) did not replicate significantly differently from rWU in vitro (Fig. 5B ) or in vivo (Fig. 5C ). However, the double mutant rWU.M F155L,V224A showed impaired viral growth kinetics in L2 cells (Fig. 5B) , and, likely as a consequence of less robust replication, an approximately 1,000-fold decrease in the viral load in the livers of infected mice compared to rWU (Fig. 5C ). Similarly, the nsp13 gene of rWU also contributed to efficient replication in vitro and in vivo. rWU.nsp13 A335V , encoding the nsp13 of JHM.SD, displayed attenuated growth kinetics in L2 cells relative to rWU as well as an approximately 30-fold lower viral titer in the livers of infected mice. Thus, sequences in the M and nsp13 proteins of JHM.WU were responsible for the enhanced replication of rSD.F WU G WU in the liver. nsp1 does not affect replication in L2 cells in vitro but influences viral replication in the liver. As described above, fragments F and G were insufficient for restoring rSD replication in the liver to the level of rWU, and there were no amino acid differences between the fragment B-, D-, and E-encoded proteins of JHM.SD and JHM.WU. These data suggested that WU fragment(s) A and/or C was likely to contribute to liver replication. To test this, we generated chimeric viruses in the rWU background in which fragment A or C was replaced with the corresponding JHM.SD fragment (Fig. 6A ). Both rWU.C SD and rWU.A SD showed growth kinetics similar to those of rWU in L2 cells; however, rWU.A SD was also significantly attenuated (approximately 100-fold) for replication in the liver ( Fig. 6B and C) . Four amino acid differences between JHM.WU and JHM.SD were identified in the A fragment (nsp1, nsp2, and nsp3), and mutations corresponding to these differences were introduced into the rWU genome to generate rWU.nsp1 K194R , rWU.nsp2 L282V , rWU.nsp2 V326A , and rWU.nsp3 H173P (Fig. 6A ). All four viruses replicated with similar kinetics and to a similar final titer as rWU in vitro in L2 cells (Fig. 6B ), indicating that polymorphisms in nsp1, nsp2, or nsp3 had no detectable effect on in vitro replication.
While there were no detectable effects on liver replication observed during infection with nsp2 or nsp3 mutants, attenuation of liver replication (approximately 100-fold) was observed in mice infected with rWU.nsp1 K194R compared with rWU ( Fig. 6C ). rWU.nsp1 K194R replicated in the liver to a similar extent as rWU. A SD and rSD.F WU G WU (which contains fragments A through E from rSD), indicating that the nsp1 amino acid substitution alone is sufficient to account for the attenuation (relative to rWU) of the latter two chimeric viruses. To further investigate the impact of nsp1 residue 194 on pathogenesis, the reverse substitution was introduced into the rSD genome to generate rSD.nsp1 R194K . Sim- ilar in vitro growth kinetics was observed for rSD.nsp1 R194K and rSD in L2 cells (Fig. 6D ). However, rSD.nsp1 R194K replicated to a significantly higher titer in mouse liver (Fig. 6E ) (rSD was undetectable, as in previous figures). As the nsp1 residue K194 is conserved among all MHV strains except JHM.SD (see Fig. 8 and Discussion), the same K194R substitution was introduced into the genome of recombinant A59 (rA59), another hepatotropic strain used frequently for MHV pathogenesis studies, to generate A59.nsp1 K194R . The A59.nsp1 K194R mutant replicated similarly to rA59 in vitro but showed attenuated (near 100-fold) liver replication ( Fig. 6F and G) . To further understand the impact of mutations in nsp1, we constructed mutant virus A59.nsp1 R193S/K194E with substitutions introducing charge alterations into nsp1, analogous to a SARS nps1 reported in the literature (27) . However, the double mutant had a phenotype similar to that of the single mutant A59.nsp1 K194R in terms of replication both in vitro in L2 cells and in vivo in the liver (Fig. 6F and G) . Moreover, the same double substitution was introduced into nsp1 of rWU (rWU.nsp1 R193S/K194E ); as for rA59, no difference was observed between the single and double mutants in replication in either L2 cells or the liver (data not shown). These data suggest that mutation of the conserved K194 decreases virulence without affecting in vitro replication.
The nsp1 protein antagonizes IFN-␤ production during MHV infection. Previous studies showed that the MHV nsp1 protein might be involved in antagonizing the type I IFN immune response (27, 28) . To investigate whether the IFN response may be involved in the phenotype of our nsp1 mutants, we compared the replication as well as the IFN-␤ production of both rWU and rA59 with those of their respective nsp1 K194R mutants in bone marrowderived macrophages (BMM), one of the few cell types in which MHV elicits a type I IFN response (29, 30) . The rA59.nsp1 K194R and A59.nsp1 R193S/K194E mutants replicated similarly, albeit to a 6to 10-fold-lower titer than for rA59 by 24 h postinfection (Fig.  7A) . However, the replication of both mutants was restored in the absence of IFN signaling, i.e., during replication in BMM derived from IFNAR Ϫ/Ϫ mice (Fig. 7B ). A similar pattern was observed for induction of IFN-␤ expression upon infection: BMM infected with wt rA59 produced approximately 210 pg ml Ϫ1 of IFN-␤ in the culture supernatant, whereas those infected with the rA59.nsp1 K194R mutant produced 3,000 pg ml Ϫ1 of IFN-␤, presumably resulting in more robust antiviral activity. Interestingly, the effects of these mutations were less pronounced in the rWU background. We observed no difference in replication between rWU and either rWU-nsp1 K194R or rWU.nsp1 R193S/K194E (Fig.  7D ), and the difference in IFN-␤ production was also smaller (Fig.  7F) : while BMM infected with rWU produced no detectable IFN-␤ in the culture supernatant, those infected with rWU-nsp1 K194R produced 140 pg ml Ϫ1 (Fig. 7F ). Consistent with these findings, BMM infected with rSD-nsp1 R194K induced 12-fold less IFN-␤ than those infected with wt rSD (Fig. 7G) . Thus, the conserved nsp1 K194 residue found in the hepatotropic rWU and rA59, while not important for replication in the L2 cell line in vitro, was associated with lower IFN-␤ production in BMM as well as higher liver titers.
DISCUSSION
Infection of mice with laboratory strains of MHV causes hepatitis and encephalitis in a strain-specific manner. JHM.SD and JHM. WU are very closely related isolates with strikingly different in vitro replication and in vivo hepatovirulence phenotypes, likely reflecting the passage history of the two isolates since their derivation from the same JHM isolate, which had been brain adapted by many serial passage through suckling mouse brains (31) . MHV-4 (from which recombinant JHM.SD was derived) was plaque purified from the mouse brain-passaged virus, while JHM.WU (wb-3) was serially passaged 20 times in tissue culture before plaque purification (5, 15, 16, 32) . The passage history coupled with data presented here suggest that adaptation to mouse brain may select for variants unable to replicate efficiently in tissue culture or in the liver. This is consistent with our previous work in which nonhepatotropic variants of rA59 were selected by passage in primary glial cell cultures (22, 23) .
Using reverse genetic systems, we constructed chimeric recombinant viruses and used them to identify the JHM.WU-encoded determinants of efficient replication in tissue culture and of liver pathogenesis. There were remarkably few amino acid differences between the proteins encoded by these two viruses. The 3= third of the JHM.WU genome, encoding the structural proteins, was necessary for efficient in vitro replication, whereas replication to a high titer in the liver was multifactorial and mapped to amino acid substitutions in the membrane (M) structural protein as well as in nonstructural replicase proteins (nsp1 and nsp13) (27, 28, 33) .
We initially hypothesized that the spike protein, which is responsible for receptor binding and viral entry, would define the difference in tropism between JHM.SD and JHM.WU. Indeed, numerous past studies demonstrated that sequences in several domains of the MHV spike impact tropism and virulence (8, 16, (34) (35) (36) (37) . The high neurovirulence of JHM.SD has been associated with the long hypervariable domain in the S1 subunit of the JHM spike protein (7, 34) . Surprisingly, JHM.WU is highly neurovirulent despite the 141-amino-acid deletion in the hypervariable domain, and our data indicate that the JHM.WU spike does not confer hepatotropism; although the JHM.WU spike enhanced replication of rSD.S WU to some extent in cell culture ( Fig. 3B and  D) , there was no significant effect on replication in the liver (Fig.  3C and E) . Similarly, a chimeric rSD expressing the spike of hepatotropic MHV-A59 was not able to replicate in the liver (13) . These results indicated that MHV replication in the liver is largely determined by postentry events and that attenuation of replication in vitro may not predict poor viral replication in vivo. Interestingly, while JHM.SD replicates poorly in vitro and minimally in the liver, it replicates well in the central nervous system, where it spreads extensively and efficiently throughout the brain, in multiple cell types, even in the absence of the only known MHV receptor, CEACAM1a (38, 39) . While difficult to explain on a mechanistic level, this likely reflects a very strong selection for the ability to replicate in the brain resulting from serial brain passage.
The membrane protein (M), the most abundant component of the virion, is key to viral particle assembly through interactions with spike (40) and nucleocapsid (41) as well as M-M interactions (42) and may, in addition, interact with the viral RNA (43, 44) through the carboxy-terminal tail of the protein. Consistent with the role of M in virus assembly, an M protein mutant of SARS-CoV, selected by serial passage in primary human renal tubular epithelial cells, was associated with persistent infection and enhanced virus production (45) . The combined introduction of two JHM.SD amino acid substitutions together into the carboxy-ter-minal endodomain of rWU M protein (rWU.M F155L,V224A ) impaired replication in L2 cells and quite dramatically in the mouse liver, although neither substitution alone conferred any detectable phenotype (Fig. 5 ). While rWU.M F155L,V224A replicated moderately less well than rWU in L2 cells, it was about 1,000fold attenuated in the liver, suggesting that other virus-host interactions in addition to virus assembly were contributing to the loss of replication in the liver. Interestingly, a study of MHV-A59 M protein glycosylation variants correlated replication in the liver with induction of type I interferon (46) . Future studies will address whether mutations within M (as well as nsp1 [discussed below]) contribute to the differences observed in IFN production during JHM.SD versus JHM.WU infection of BMM ( Fig. 7F and G) .
We also identified amino acid differences between the JHM.SD and JHM.WU genomes within nonstructural proteins (Table 1) . Among these, only the JHM.SD-specific amino acid substitutions in nsp1 and nsp13 influenced the phenotype. Introduction of an A335V substitution into the helicase domain of JHM.WU nsp13 attenuates viral replication both in vitro and in vivo (47) (Fig. 5 ). As the A335V substitution confers less efficient replication in vitro, it is likely that the in vivo effects are due to less efficient replication. Consistent with a role of nsp13 in contributing to efficient replication, nsp13 mutations were identified during the emergence of SARS-CoV into the human population and in mouse-adapted strains, which replicate more efficiently in the lung (48, 49) .
Nsp1 is the N-terminal cleavage product of the replicase poly-protein and is encoded by all betacoronaviruses. While nsp1 varies in length, from 247 residues in MHV to 175 in bat CoV-HKU9, certain regions are conserved (20) . The K194 residue of MHV nsp1 is located in a positively charged domain (LLRK 194 GGNKG), is relatively conserved among betacoronaviruses (Fig. 8) , and is presumed to be involved in RNA binding and/or protein-protein interactions (50, 51) . The K194 residue of MHV nsp1 is conserved among all MHV isolates except JHM.SD (with its K194R substitution) and also throughout other betacoronaviruses (Fig. 8 ). We (52) (53) (54) (55) and that this may in part be conferred by nsp1 (20) . Data from our lab suggested that MHV-A59 inhibits IFN protein production at the translational level (53) . In other studies, MHV-A59 mutants either with a deletion of the LLRK 194 GGNKG domain (56) or with an internal downstream 33-amino-acid in-frame deletion (28) were attenuated for liver replication as well as the onset of hepatitis in wild-type mice, while the latter deletion mutant recovered replication in type I IFN receptor expression-deficient (IFNAR Ϫ/Ϫ ) mice (28) . In addition, transient expression of MHV or SARS-CoV nsp1 significantly reduced expression of a luciferase reporter gene under the control of the IFN-␤ or IFN-stimulated response element (ISRE) promoter (28) , implying that nsp1 may antagonize the type I interferon signaling pathway. Furthermore, the importance of residues R193/K194 for virulence via IFN antagonism is supported by the finding that a SARS-CoV mutant expressing nsp1 with amino acid substitutions of these conserved residues (R124S/K125E, corresponding to residues 193/194 of MHV nsp1) was more sensitive than wt virus to type I IFN treatment (27) . In another group of studies, the nsp1 of SARS-CoV was reported to promote mRNA degradation and to inhibit protein translation, thereby inhibiting IFN-␤ production at both the mRNA and protein levels (33, (57) (58) (59) (60) , while an nps1 mutant (R124A/K125A) was unable to degrade mRNA but retained the ability to inhibit protein synthesis. Thus, the effects of nsp1 on transcription and translation are complex and may be coronavirus strain type dependent (20) .
Interestingly, the attenuation phenotype conferred by mutation of nsp1 is observed only in the livers of infected mice and not in the brains. In our studies following intracranial infection, while rWU.nsp1 K194 was significantly attenuated for liver replication compared to rWU, there were no significant differences observed in replication of the two viruses in the brain (data not shown). This is similar to the phenotype of an A59 ns2 PDE mutant, which replicates robustly in the brain while being highly attenuated for liver replication and hepatitis (12, 30) . The liver-specific attenuation of these mutants, both deficient in type I IFN antagonism, is likely explained by our previous finding that basal levels of interferon-stimulated gene expression are much higher in the liver than in the brain, leading to a more robust host innate response in the liver than in the brain (14, 30) The mechanism by which MHV nsp1 interferes with the type I IFN response and its role in liver tropism are not yet well understood and will be a subject of further investigation.
Elucidating the mechanisms underlying tropism and virulence using these model coronaviruses may also contribute to our knowledge of the pathogenesis of the human-pathogenic coronaviruses such as SARS-CoV or MERS-CoV, as the LRKGGNKG motif of nsp1 as well as the nsp13 helicase and M protein are conserved among these viruses. Understanding these virulence determinants may in the long term contribute to the design of live attenuated vaccines for coronaviruses.
